Table 5 G2 at week 6, 7 and 2 weeks after RT in BC and HNC patients
Visit | Statistics | BC | HNC | ||
|---|---|---|---|---|---|
SOC | Xonrid® + SOC | SOC | Xonrid® + SOC | ||
WEEK 6 | NO G2 | 3 (16.7%) | 7 (38.9%) | 6 (37.5%) | 9 (45.0%) |
G2+ | 15 (83.3%) | 11 (61.1%) | 10 (62.5%) | 11 (55.0%) | |
p-value (Chi-square) | 0.1 | 0.6 | |||
Logistic regression | Odds ratio | 0.31 | 0.73 | ||
95% CI | 0.07–1.50 | 0.19–2.81 | |||
p-value | 0.1 | 0.6 | |||
WEEK 7 | NO G2 | 3 (21.4%) | 5 (25.0%) | ||
G2+ | 11 (78.6%) | 15 (75.0%) | |||
p-value (Chi-square) | 0.8 | ||||
Logistic regression | Odds ratio | 0.82 | |||
95% CI | 0.16–4.17 | ||||
p-value | 0.8 | ||||
2 WEEKS AFTER END OF TREATMENT | NO G2 | 3 (16.7%) | 6 (35.3%) | 12 (100.0%) | 15 (100.0%) |
G2+ | 15 (83.3%) | 11 (64.7%) | |||
p-value (Chi-square) | 0.2 | ||||
Logistic regression | Odds ratio | 0.37 | |||
95% CI | 0.07–1.80 | ||||
p-value | 0.2 | ||||